The same molecule, two brands, a sevenfold price gap

Oral semaglutide is now sold under more than one brand at wildly different prices: the reformulated pill reportedly launched near $149 a month while Rybelsus, the original oral semaglutide brand, still lists close to $998.

Same active molecule, same manufacturer, roughly a sevenfold difference. That is not a pricing error; it is what happens when a manufacturer launches a new brand into a cash-pay market while an older brand remains priced for the insured channel.

The practical instruction is unusually concrete. If you are prescribed oral semaglutide, the brand written on the prescription matters enormously to what you pay, and it is worth asking your prescriber explicitly which one they intend to write.

It is also a warning about price comparisons in this category generally: 'semaglutide costs X' is a meaningless sentence without naming the product and the channel.

How to read a pricing story in this market

Pricing stories are the fastest-moving and worst-reported in this category. A figure quoted without a date, a dose and a product name is not a price, and most coverage supplies none of the three — which matters more for semaglutide than for most molecules, because the same active ingredient is sold under at least four brands at wildly different prices.

The specific failure to watch for is a promotional or prepaid rate presented as a standing monthly figure. It understates a year by hundreds of dollars and it is the single most common error we correct.

What this does not change

The prescription requirement, the licensing framework behind a dispensing pharmacy, and the clinical review that should sit in front of any prescription. Those are stable and none of the developments we track has altered them.

It also does not change the arithmetic of choosing a programme: price the dose you expect to hold, add every recurring fee, and verify the pharmacy. The cheapest verified route we track is NexLife at $145 a month all-in at a maintenance dose, about $1,740 for a first year.

Where a development does move those figures, the tables regenerate from the dataset on the next build rather than being edited by hand.

When urgency is the product

Regulatory and market news is routinely used as a sales device. A programme citing a rule change to push you into a twelve-month prepayment is using a real fact to manufacture a deadline that does not apply to you.

The test is simple: does the development change what you can lawfully be prescribed this month? Almost never. Does it change what you should pay? Sometimes. Does it require you to decide today? Essentially never — and a programme insisting otherwise has told you how it treats patients under commercial pressure.

How much pricing should weigh

Less than the dose question and more than the brand. 19 of 20 programmes hold one price from 0.25 mg to 2.4 mg; the rest reprice as you climb. Which group you choose changes a twelve-month total more than almost any other single decision.

That is because semaglutide titrates slowly. Sixteen weeks minimum to a maintenance dose, frequently longer for tolerability, and a dose-scaled programme reprices you at every step of it.

Flat pricing is worst value at the bottom of the ladder and best at the top, which makes it less a lower price than insurance against a decision your prescriber has not made yet.

What a well-run programme publishes

Its price at every strength. Its pharmacy. Its prescriber's licensure. Its cancellation notice period. And which form of the active ingredient it compounds from, because FDA has distinguished semaglutide base from salt forms and linked the salts to safety concerns.

That last one is specific to this molecule and almost never asked. Programmes that answer it precisely are telling you how closely they supervise their supply chain.

What the spread actually represents

All-in cost runs $145 to $324 a month for the same molecule from the same category of licensed pharmacy. That gap is not the medicine. It is overhead, clinical wrap, sourcing and margin, plus how aggressively a programme is willing to structure its fees.

4 of 20 charge a mandatory recurring fee and 19 hold one price at every strength. Those two facts explain most of the spread, and neither appears in a headline figure.

Where our numbers could be wrong

A programme changed its price after our capture date. A third-party figure we recorded does not survive checking. A promotional rate was published as a standing one. Or a programme publishes something we could not find.

All four are live risks and the first is near-certain over time. Every figure carries its capture date and a link to the source we read, so the check takes about two minutes and does not require trusting us.

Why the cheapest entries are the least reliable

Four distortions push in the same direction: a promotional first month quoted as a standing rate, a prepaid bundle rate quoted as monthly, a medication figure that excludes a mandatory membership, and occasionally a different molecule's price in the wrong column.

Every one of those makes a programme look cheaper than it is, which is why the bottom of any published table is where errors concentrate. It is also why we mark which figures we read at the provider and which we did not, rather than presenting one confident list.

Where we have been able to check an unconfirmed figure against a provider's own page, the number usually moved upward.

How to sanity-check any figure you find elsewhere

Three questions. What dose does it describe? Does it include every recurring fee? And when was it captured? A price failing any of the three is not comparable to the numbers here, and most published figures fail at least one.

Semaglutide makes this worse than most categories because the same molecule sells under several brands at prices spanning more than fifteenfold. 'Semaglutide costs X' is not a sentence that can be true without naming the product and the channel.

What this changes for what you pay

Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.

The cheapest verified compounded route we track currently sits at $145 a month all-in at a 2.4 mg maintenance dose, about $1,740 for a first year. Where a development moves that figure, our tables move with it on the next build.

How to verify this yourself

Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.

Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.